| |
Allicor
|
Placebo
|
|---|
|
Time
|
All
|
Men
|
Women
|
All
|
Men
|
Women
|
|---|
| |
(n = 26)
|
(n = 14)
|
(n = 12)
|
(n = 25)
|
(n = 14)
|
(n = 11)
|
|---|
|
Absolute risk, %
|
|
At the baseline
|
13.1 ± 3.8
|
22.3 ± 6.0
|
2.3 ± 0.6$
|
8.9 ± 2.4
|
14.3 ± 3.7
|
2.0 ± 0.7$
|
|
After 12 months
|
8.9 ± 2.3*
|
15.1 ± 3.5*
|
1.8 ± 0.6$
|
7.8 ± 2.4*
|
12.4 ± 3.9*
|
1.9 ± 0.6$
|
|
Relative risk
|
|
At the baseline
|
1.00
|
1.00
|
1.00
|
1.00
|
1.00
|
1.00
|
|
After 12 months
|
0.81 ± 0.08*
|
0.76 ± 0.08*
|
0.88 ± 0.15
|
1.05 ± 0.13
|
0.81 ± 0.10
|
1.36 ± 0.23$
|
- * - a significant difference from the baseline, paired Wilcoxon test, P < 0.05;
- $ - a significant within-group difference between men and women, t-test, P < 0.05.
